Medigus Surges Most in Four Months on FDA Approval Request
Medigus Ltd. (MDGS) surged the most in more than four months after the company said it will seek U.S. Food and Drug Administration approval to market its SRS device for the treatment of gastro-esophageal reflux disease.
Shares of the maker of endoscopic procedures and devices rallied 16 percent, the most since Sept. 11, to 0.698 shekel at 10:38 a.m. in Tel Aviv.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.